SEHK:2616Biotechs
Is CStone Pharmaceuticals (SEHK:2616) Turning Sugemalimab Data Into a Sustainable Immuno-Oncology Edge?
EQRx, based in Cambridge, USA, previously reported new clinical trial data for its lung cancer candidate sugemalimab, a monoclonal antibody developed in collaboration with CStone Pharmaceuticals, with plans to present the findings at the World Conference on Lung Cancer 2021.
The therapy’s design to mirror a naturally occurring antibody, potentially lowering immunogenicity and toxicities, highlights CStone’s exposure to differentiated immuno-oncology innovation through this partnership.
We’ll...